XASECPHI
Market cap3mUSD
Dec 23, Last price
0.18USD
1D
3.45%
1Q
-17.96%
Jan 2017
-30.77%
Name
China Pharma Holdings Inc
Chart & Performance
Profile
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
IPO date
Feb 15, 2000
Employees
234
Domiciled in
CN
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 7,011 -13.48% | 8,104 -15.95% | 9,642 -11.27% | |||||||
Cost of revenue | 9,779 | 11,747 | 12,758 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (2,768) | (3,643) | (3,116) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 6,249 | 542 | ||||||||
Tax Rate | ||||||||||
NOPAT | (2,768) | (9,892) | (3,658) | |||||||
Net income | (3,079) -69.88% | (10,222) 159.34% | (3,941) 24.69% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,650 | 1,707 | ||||||||
BB yield | -403.02% | -338.69% | ||||||||
Debt | ||||||||||
Debt current | 3,182 | 8,757 | 7,194 | |||||||
Long-term debt | 1,569 | 40 | 5,424 | |||||||
Deferred revenue | (5,250) | |||||||||
Other long-term liabilities | 5,250 | |||||||||
Net debt | 3,328 | 6,768 | 7,758 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (700) | (410) | (250) | |||||||
CAPEX | (12) | (402) | (438) | |||||||
Cash from investing activities | (12) | (402) | (438) | |||||||
Cash from financing activities | 73 | (1,770) | 4,598 | |||||||
FCF | (1,941) | (5,618) | (2,357) | |||||||
Balance | ||||||||||
Cash | 1,424 | 2,030 | 4,859 | |||||||
Long term investments | ||||||||||
Excess cash | 1,073 | 1,625 | 4,377 | |||||||
Stockholders' equity | (27,828) | (24,564) | (19,627) | |||||||
Invested Capital | 39,916 | 36,545 | 37,292 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 3,384 | 5,257 | 4,613 | |||||||
Price | 0.12 26.17% | 0.10 -80.13% | 0.48 8.25% | |||||||
Market cap | 409 -18.79% | 504 -77.35% | 2,226 14.47% | |||||||
EV | 3,737 | 7,272 | 9,985 | |||||||
EBITDA | (14) | (942) | (28) | |||||||
EV/EBITDA | ||||||||||
Interest | 334 | 424 | 542 | |||||||
Interest/NOPBT |